Oculis (NASDAQ:OCS) Stock Price Down 1.1% - What's Next?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) traded down 1.1% during trading on Wednesday . The company traded as low as $18.37 and last traded at $18.43. 10,438 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 45,351 shares. The stock had previously closed at $18.64.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on OCS shares. Robert W. Baird upped their target price on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research report on Thursday, March 13th. HC Wainwright increased their price objective on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th. Finally, Chardan Capital lifted their target price on shares of Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, May 9th.

Oculis Price Performance

The company has a market cap of $804.65 million, a price-to-earnings ratio of -6.98 and a beta of 0.29. The firm has a fifty day simple moving average of $18.95 and a 200 day simple moving average of $19.22.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. Analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

A number of institutional investors have recently made changes to their positions in OCS. Bellevue Group AG acquired a new stake in Oculis in the 4th quarter valued at approximately $170,000. XTX Topco Ltd bought a new stake in shares of Oculis in the fourth quarter valued at approximately $225,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Oculis in the first quarter worth $234,000. Geode Capital Management LLC increased its position in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the period. Finally, Citadel Advisors LLC bought a new position in Oculis during the fourth quarter worth $389,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.